Patent Appeals Strategy

After receiving a final rejection in patent prosecution, a patentee has several options — each with different costs, timelines, and strategic implications: OPTION 1 — AFCP 2.0 (AFTER FINAL CONSIDERATION PILOT): WHAT IT IS: a pilot program allowing applicants to file a non-broadening amendment after final rejection without abandoning the application; COST: no USPTO fee; WHAT IS REQUIRED: amendment that does not broaden any claim; a request for consideration under AFCP 2.0; a showing of how the amendment addresses the final rejection; WHAT THE EXAMINER DOES: examiner has 3 additional hours to consider the amendment; may conduct an interview (this is one of the biggest values — AFCP 2.0 greatly increases the chance of an examiner interview); if amendment places application in condition for allowance = allowed; if not = examiner explains; you have NOT changed your appeal rights; BEST USE CASE: when you can add a small limiting amendment that clearly distinguishes the prior art AND you want to have an interview with the examiner to understand why your claims were rejected; can be combined with a pre-appeal brief if AFCP 2.0 fails; OPTION 2 — PRE-APPEAL BRIEF CONFERENCE (PABC): WHAT IT IS: a 2-page brief requesting a conference of 3 examiners to review the final rejection before filing a full appeal; COST: no USPTO fee; filing brief: $3,000-$8,000 attorney fees; WHEN: must file within 2 months of final rejection (same period as response to final rejection); WHAT IT DOES: a panel of three examiners (the primary examiner + two others) reviews the brief; options: enter appeal; reopen prosecution; allow the application; resolves ~40% of cases without reaching PTAB; BEST USE CASE: when the rejection is clearly wrong on established legal grounds (examiner misread the prior art; wrong claim construction; § 101 rejection that the 2019 Revised Guidance clearly contradicts); OPTION 3 — NOTICE OF APPEAL TO PTAB: WHEN: within 2 months of final rejection (extendable with fees up to 5 months total); COST: $860 (small entity; Notice of Appeal) + $1,000 (small entity; appeal brief); + attorney fees for brief preparation $10,000-$25,000; TIMELINE: 18-36 months from filing Notice of Appeal to PTAB decision (varies by art unit and PTAB docket); OUTCOME: reversal of rejection; affirmance; new ground of rejection; OPTION 4 — REQUEST FOR CONTINUED EXAMINATION (RCE): WHEN: after final rejection; COST: $900 (small entity; first RCE); $900 (second RCE small entity); + filing fee; attorney fees; EFFECT: prosecution reopens; application is back before examiner with new prosecution cycle; CAN PROCEED WITH: new amendments; new arguments; new evidence (§ 1.132 declarations); DOWNSIDE: creates C-delay in patent term adjustment (PTA) calculation — any delay caused by RCE is not compensable PTA; OPTION 5 — CONTINUATION APPLICATION: file a continuation with different claim scope before the parent issues; preserves priority date; allows fresh examination with different claim language; CAN COMBINE: many applicants file Notice of Appeal + continuation simultaneously (appeal protects current claims; continuation tests new claim approaches).

A PTAB ex parte appeal is the formal mechanism for challenging a USPTO examiner's rejections before the Patent Trial and Appeal Board — a multi-APJ (Administrative Patent Judge) panel rather than a single examiner: WHO DECIDES PTAB EX PARTE APPEALS: a panel of typically three APJs (Administrative Patent Judges); APJs are typically patent attorneys with technical backgrounds in the relevant art; the original examining corps is not part of the PTAB panel; WHAT PTAB REVIEWS: PTAB reviews whether the examiner's rejections were correct; de novo review of legal issues; deferential review of fact findings; PTAB can review: anticipation (§ 102); obviousness (§ 103); § 101 patent eligibility; § 112 written description; § 112 enablement; § 112 indefiniteness; double patenting; EX PARTE APPEAL BRIEF REQUIREMENTS: statement of facts (correct description of prosecution history); claim groupings (groups claims together for argument efficiency); argument section (one argument per distinct rejection; grouped claims); 37 C.F.R. § 41.37 technical requirements; 25-page limit (or request waiver); AFTER THE APPEAL BRIEF: Examiner's Answer: examiner files an Answer responding to the appeal brief; can contain new grounds of rejection; if new grounds → applicant has 2 months to respond or maintain the appeal; Reply Brief: optional; applicant responds to examiner's Answer; strict time limit; ORAL HEARING: applicant may request oral argument before PTAB panel; 30-minute presentation; allows direct questioning by APJs; useful for complex claim construction disputes; TYPICAL PTAB OUTCOMES: REVERSAL OF ALL REJECTIONS: all rejected claims found allowable; application returns to examiner for allowance; NEW GROUND OF REJECTION: PTAB finds a rejection that the examiner did not make; applicant has two options: (a) reopen prosecution (respond to new ground before examiner); or (b) request rehearing by PTAB panel; AFFIRMANCE: PTAB agrees with examiner; all rejections confirmed; applicant must then: appeal to Federal Circuit OR file RCE + amend; REVERSAL STATISTICS: overall PTAB ex parte appeal reversal rates: approximately 30-40% of claims receive some reversal; technology-specific variation: § 101 software rejections reversed more often since Alice guidance; § 102/103 reversals depend heavily on claim construction precision; STRATEGIC VALUE OF PTAB APPEAL: beyond the reversal rate, filing a PTAB appeal demonstrates seriousness; many cases settle at the examiner's answer stage or immediately after oral argument; PTAB decisions create a written record that may be useful if the patent is later litigated.

Federal Circuit appeals from PTAB inter partes review (IPR) final written decisions are significant litigation tools for both petitioners (challenging patents) and patent owners (defending patents) — and the Federal Circuit has developed extensive IPR-specific appellate doctrine: WHO CAN APPEAL: both the petitioner (if patent was NOT cancelled) and the patent owner (if patent WAS cancelled or claims amended) can appeal a final written decision (FWD); parties must have participated in the IPR; SCOPE OF FEDERAL CIRCUIT REVIEW: LEGAL ISSUES: de novo review (PTAB's legal conclusions reviewed without deference); includes: claim construction (now under Phillips standard); § 101 patent eligibility; § 112 requirements; FACTUAL FINDINGS: clear error review (PTAB's factual findings reversed only if clearly erroneous); includes: obviousness motivation to combine; scope and content of prior art; secondary considerations; INSTITUTION DECISION: Cuozzo Speed Technologies v. Lee (S.Ct. 2016): PTAB's decision to institute IPR is not reviewable on appeal; but PTAB's authority to decide a case can be challenged; Thryv v. Click-to-Call (S.Ct. 2020): § 315(b) time bar determinations = not reviewable; ARTHREX v. SMITH & NEPHEW (S.Ct. 2021): APJ appointments were unconstitutional as APJs wielded significant executive power without proper presidential appointment; REMEDY: Director can now review any PTAB decision; parties can seek Director review as a new procedural step before Federal Circuit; COMMON GROUNDS FOR APPEAL FROM PTAB IPR: CLAIM CONSTRUCTION: petitioner may appeal arguing PTAB construed claims too narrowly; patent owner may appeal arguing claims construed too broadly; Federal Circuit decides claim construction de novo; claim construction changes on appeal can flip the outcome; MOTIVATION TO COMBINE: Federal Circuit reviews underlying factual findings for clear error; but may review de novo the legal conclusion of obviousness; Belden v. Berk-Tek LLC (key case on motivation to combine); SECONDARY CONSIDERATIONS: objective indicia of non-obviousness must be weighed; failure to consider secondary considerations = reversible error; FEDERAL CIRCUIT REVERSAL RATES FROM PTAB IPR: approximately 15-25% of appealed FWDs are reversed in whole or part; approximately 60-70% are affirmed; the rest are remanded; TIMING: Federal Circuit appeals typically resolved in 12-18 months after briefing complete; CERTIORARI TO SUPREME COURT: patent cases from Federal Circuit can petition for cert; granted rarely (Oil States Energy Services v. Greene's Energy — SCOTUS 2018 upheld IPR constitutionality; Arthrex APJ appointments; Samsung v. Apple design patent; Amgen v. Sanofi enablement); STRATEGIC USE OF FEDERAL CIRCUIT APPEAL: patent owner: if PTAB cancels claims, appeal buys 12-18 months of continued patent protection while on appeal; petitioner: if PTAB maintains patent and district court infringement case was stayed, Federal Circuit appeal forces patent owner to continue defending validity on two fronts.

The Director Review mechanism was created by the Supreme Court's 2021 Arthrex decision as a constitutional remedy for the fact that APJs had been exercising significant executive power without proper presidential appointment: THE ARTHREX PROBLEM: APJs are appointed by the Secretary of Commerce (a department official) rather than the President with Senate confirmation; the Supreme Court held this was unconstitutional because APJs exercise significant executive power (they can cancel patents, which is a significant final agency action); THE REMEDY — DIRECTOR REVIEW: rather than invalidating all IPR decisions, the Court held that the remedy is to give the USPTO Director power to review and correct any PTAB APJ decision; result: any party can now request Director Review of a PTAB decision; HOW DIRECTOR REVIEW WORKS: after a PTAB final written decision (or institution decision), any party can request Director Review; the Director (or delegated designee) reviews the PTAB decision; the Director can: affirm; reverse; modify; or remand to the PTAB; no fixed timeline for Director Review (adds some uncertainty); PTAB PRECEDENTIAL OPINION PANEL (POP): separately from Arthrex, the POP is a mechanism for the Director to convene a special panel to address legal issues across multiple PTAB proceedings; POP decisions become binding on future PTAB panels; significantly more important now that Director has explicit review authority; STRATEGIC IMPLICATIONS: INSTITUTION DENIAL REVIEW: if PTAB denies institution (particularly on Fintiv grounds), petitioner can request Director Review; Director has signaled willingness to review Fintiv denials; important tool for petitioners denied institution near start of trial; PATENT OWNER REVIEW REQUESTS: if PTAB cancels claims, patent owner should consider Director Review before Federal Circuit appeal; Director Review does not require briefing in Federal Circuit (preserves Federal Circuit option); FINTIV FACTOR CHANGES: Director has issued guidance modifying the Fintiv analysis; Director Review provides a mechanism to challenge Fintiv denials; DUDAS v. IANCU LINEAGE: the political appointee Director (confirmed by Senate) changes with administrations; Director Review practice may vary based on Director's patent policy priorities; CURRENT DIRECTOR REVIEW STATUS: as of 2024, Director Review is actively used; several high-profile Director reversals of PTAB decisions have occurred; petition statistics: hundreds filed per year; Director grants review in a small fraction; INTERACTION WITH FEDERAL CIRCUIT: Director Review does not replace Federal Circuit appeal; Federal Circuit appeal is available AFTER Director Review if Director affirms PTAB; some uncertainty about timing of Federal Circuit jurisdiction when Director Review is pending; best practice: file notice of appeal within statutory deadline while requesting Director Review to preserve both options.